HDAC9 and ovarian cancer: Herein we demonstrate that gynecologic cancer cell lines, xenografted animal models, and patient-derived organoids (PDOs) of endometrial and ovarian cancer have differential sensitivity to the combination of the FDA-approved proteasome inhibitor ixazomib and the FDA-approved HDAC inhibitor romidepsin based upon their ability to induce autophagy as a survival mechanism.